Miners JO - Search Results

1

Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.

Miners JO, Coulter S, Birkett DJ, Goldstein JA. Miners JO, et al. Pharmacogenetics. 2000 Apr;10(3):267-70. doi: 10.1097/00008571-200004000-00008. Pharmacogenetics. 2000. PMID: 10803683 No abstract available.

2

Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques.

Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez FJ, Miners JO. Tassaneeyakul W, et al. Among authors: miners jo. Pharmacogenetics. 1992 Aug;2(4):173-83. doi: 10.1097/00008571-199208000-00004. Pharmacogenetics. 1992. PMID: 1306118

3

Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.

Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ. Miners JO, et al. J Pharmacol Exp Ther. 1995 Mar;272(3):1076-81. J Pharmacol Exp Ther. 1995. PMID: 7891318

4

Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2.

Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Miners JO. Tassaneeyakul W, et al. Among authors: miners jo. Pharmacogenetics. 1994 Oct;4(5):281-4. doi: 10.1097/00008571-199410000-00007. Pharmacogenetics. 1994. PMID: 7894501 No abstract available.

5

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. Sullivan-Klose TH, et al. Among authors: miners jo. Pharmacogenetics. 1996 Aug;6(4):341-9. doi: 10.1097/00008571-199608000-00007. Pharmacogenetics. 1996. PMID: 8873220

6

Allelic and functional variability of cytochrome P4502C9.

Bhasker CR, Miners JO, Coulter S, Birkett DJ. Bhasker CR, et al. Among authors: miners jo. Pharmacogenetics. 1997 Feb;7(1):51-8. doi: 10.1097/00008571-199702000-00007. Pharmacogenetics. 1997. PMID: 9110362

7

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Miners JO, Birkett DJ. Miners JO, et al. Br J Clin Pharmacol. 1998 Jun;45(6):525-38. doi: 10.1046/j.1365-2125.1998.00721.x. Br J Clin Pharmacol. 1998. PMID: 9663807 Free PMC article. Review.

8

Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

Elliot DJ, Suharjono, Lewis BC, Gillam EM, Birkett DJ, Gross AS, Miners JO. Elliot DJ, et al. Among authors: miners jo. Br J Clin Pharmacol. 2007 Oct;64(4):450-7. doi: 10.1111/j.1365-2125.2007.02943.x. Epub 2007 May 22. Br J Clin Pharmacol. 2007. PMID: 17517049 Free PMC article.

9

Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity.

Kerdpin O, Elliot DJ, Boye SL, Birkett DJ, Yoovathaworn K, Miners JO. Kerdpin O, et al. Among authors: miners jo. Biochemistry. 2004 Jun 22;43(24):7834-42. doi: 10.1021/bi0496844. Biochemistry. 2004. PMID: 15196026

10

Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450.

Veronese ME, McManus ME, Laupattarakasem P, Miners JO, Birkett DJ. Veronese ME, et al. Among authors: miners jo. Drug Metab Dispos. 1990 May-Jun;18(3):356-61. Drug Metab Dispos. 1990. PMID: 1974199

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

266 results

Search Page